Evidence for a potent antiinflammatory effect of rosiglitazone

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2728-2835

  Mohanty, Priya ^a   Aljada, Ahmad ^a   Ghanim, Husam ^a   Hofmeyer, Deborah ^a   Tripathy, Devjit ^a   Syed, Tufail ^a   Al Haddad, Waddah ^a   Dhindsa, Sandeep ^a   Dandona, Paresh ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Diabetes Endocrinology Center of Western New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMYLOID A PROTEIN; ATENOLOL; ATORVASTATIN; BENAZEPRIL; C REACTIVE PROTEIN; CELECOXIB; COLCHICINE; DILTIAZEM; FLUOXETINE; GLIBENCLAMIDE; IBUPROFEN; IMIPRAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LISINOPRIL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN; NUCLEAR FACTOR; OMEPRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; QUINAPRIL; ROSIGLITAZONE; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALSARTAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; BINDING AFFINITY; BLOOD LEVEL; BLOOD SAMPLING; CELL LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MEASUREMENT; MONOCYTE; MONONUCLEAR CELL; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHEMOKINE CCL2; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; I-KAPPA B PROTEINS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NF-KAPPA B; OBESITY; SOLUBILITY; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942655390     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032103     Document Type: Conference Paper

References (47)

1. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P 2001 Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306-1312
2. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P 2001 Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 86:3250-3256
3. Edvardsson U, Bergstrom M, Alexandersson M, Bamberg K, Ljung B, Dahllof B 1999 Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res 40:1177-1184
4. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK 1998 The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82
5. Jiang C, Ting AT, Seed B 1998 PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
6. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD 1999 A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389
7. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126
8. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H 1998 Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820
9. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y 2001 Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456
10. Grilli M, Chiu JJ, Lenardo MJ 1993 NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 143:1-62
11. Baeuerle PA, Henkel T 1994 Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141-179
12. Baeuerle PA, Baltimore D 1996 NF-κB: ten years after. Cell 87:13-20
13. Baldwin Jr AS 1996 The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649-683
14. Barnes PJ, Karin M 1997 Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
15. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA 2000 The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20:E83-E88
16. Dandona P, Thusu K, Hafeez R, Abdel-Rahman E, Chaudhuri A 1998 Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. Metabolism 47:788-791
17. Aljada A, Ghanim H, Assian E, Mohanty P, Hamouda W, Garg R, Dandona P 1999 Increased IκB expression and diminished nuclear NF-κB in human mononuclear cells following hydrocortisone injection. J Clin Endocrinol Metab 84:3386-3389
18. Dandona P, Aljada A, Ghanim H, Mohanty P, Hamouda W, Al-Haddad W 2001 Acute suppressive effect of hydrocortisone on p47 subunit of nicotinamide adenine dinucleotide phosphate oxidase. Metabolism 50:548-552
19. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, Dandona P 2000 Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36:430-435
20. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S 2001 Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265
21. DeLeo FR, Quinn MT 1996 Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leukoc Biol 60:677-691
22. Griendling KK, Sorescu D, Ushio-Fukai M 2000 NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494-501
23. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
24. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P 2000 Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970-2973
25. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M 1995 Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-290
26. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin Jr AS 1995 Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 15:943-953
27. Miller MD, Krangel MS 1992 Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17-46
28. Cross AK, Richardson V, Ali SA, Palmer I, Taub DD, Rees RC 1997 Migration responses of human monocytic cell lines to α- and β-chemokines. Cytokine 9:521-528
29. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM 1991 Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88: 2039-2046
30. Aljada A, Ghanim H, Saadeh R, Dandona P 2001 Insulin inhibits NF-κB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86:450-453
31. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ 1998 Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-281
32. Dandona P, Aljada A, Mohanty P 2002 The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924-930
33. Mohanty P, Khurana U, Chaudhuri A, Thusu K, Aljada A 1996 Non-suppresibility of reactive oxygen species (ROS) generation by mononuclear cells (MNC) in obesity. Diabetes 45(Suppl 1):171A (abstract)
34. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R 2001 The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 86:355-362
35. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB 1995 The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119
36. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB 1999 Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135
37. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T 1998 Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910
38. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM 2001 C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
39. Buchanan T, Xiang A, Petters R, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Azen S 2001 Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 50(Suppl 2):A81
40. Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D, Dandona P, Glucose induces an increase in intranuclear nuclear factor-kB (NF-kB), a fall in cellular inhibitor-kb and increase in membrane p47phox subunit. J Clin Endocrinol Metab, in press
41. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI 2002 Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684
42. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, Pearce WH 1990 Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 137:1199-1213
43. Lusis AJ 2000 Atherosclerosis. Nature 407:233-241
44. Yla-Herttuala S 1991 Biochemistry of the arterial wall in developing atherosclerosis. Ann NY Acad Sci 623:40-59
45. Rosenfeld ME 1996 Cellular mechanisms in the development of atherosclerosis. Diabetes Res Clin Pract 30(Suppl):1-11
46. Aljada A, Ghanim H, Friedman J, Garg R, Mohanty P, Dandona P 2001 Troglitazone reduces the expression of PPARγ while stimulating that of PPARα in mononuclear cells in obese subjects. J Clin Endocrinol Metab 86: 3130-3133
47. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM 1998 Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-240